CD155 Cancer Research Results

CD155, CD155: Click to Expand ⟱
Source:
Type:

CD155 (PVR; poliovirus receptor; nectin-like protein 5/NECL-5) is an immunoglobulin-superfamily cell-adhesion molecule and immune-checkpoint ligand. It binds the inhibitory receptors TIGIT and CD96, as well as the activating receptor CD226/DNAM-1, on T cells and NK cells. CD155 is frequently overexpressed in cancer, where increased expression commonly promotes immune evasion, tumour-cell migration, invasion, proliferation, and poor prognosis. For cancer records, CD155/PVR ↑ is generally tumour-promoting, while CD155 blockade or reduction is usually considered beneficial; however, the specific receptor interaction should be recorded when known. Gene reference; Cancer review.



Scientific Papers found: Click to Expand⟱
6830- EMD,    Anticancer activity of emodin is associated with downregulation of CD155
- vitro+vivo, Melanoma, B16-BL6 - in-vitro, BC, E0771 - in-vitro, BC, 4T1
TumCP↓, We found that emodin significantly decreased the expression of CD155 in tumor cells and inhibited tumor cell proliferation and migration, and induced cell-cycle arrest at G2/M phase.
TumCMig↓,
TumCCA↑,
CD155↓, Emodin inhibits CD155 expression in multiple cancer cell lines
Dose↓, 20 μM and 50 μM decreased CD155 mRNA in EO771 and 4T1 cells
other↝, Our previous study showed that emodin could significantly inhibit the growth of early-stage breast cancer and effectively suppress metastatic tumor growth at the late stage by modulating the tumor microenvironment (TME)
TumCG↓, In conclusion, we propose a new mechanism by which emodin suppresses tumor growth.


Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

CD155↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG↓, 1,  

Migration(tgid=13) ⓘ

TumCMig↓, 1,   TumCP↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↓, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: CD155, CD155
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1531  State#:%  Dir#:1
  wNotes=on  sortOrder:rid,rpid

 

Home Page